期刊
JOURNAL OF RHEUMATOLOGY
卷 36, 期 10, 页码 2171-2177出版社
J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.090054
关键词
RHEUMATOID ARTHRITIS; TUMOR NECROSIS FACTOR-alpha; SWITCH; EFFECT; REASON FOR DISCONTINUATION
类别
Objective. To investigate whether the reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent influences the effect of a second TNF blocking agent. Methods. Data were used from 2 Dutch registries including patients with rheumatoid arthritis (RA) treated with TNF blocking agents. Patients were divided into 3 groups based on reason for discontinuation of the first: nonresponse, loss of response, or adverse events. The primary outcome was the change from baseline of the disease activity (by DAS28) at 6 months, corrected for the baseline DAS28 score. Secondary outcomes were the change from baseline at 3 months, EULAR response rates, and the percentages of patients who reached a DAS28 score <= 3.2 at 3 and at 6 months. Results. In total, 49 patients who failed due to nonresponse, 75 due to loss of response, and 73 due to adverse events were included. At 6 months, the change of DAS28 score from baseline did not differ significantly between the groups (-0.6 to -1.3-, p >= 0.173) and similar good and moderate response rates were found (12% to 18%, p >= 0.523, and 34% to 55%, p >= 0.078, respectively). The secondary outcomes were also comparable between the 3 groups. Conclusion. The results of our observational Study suggest that a second TNF blocking agent may be effective after failure of the first, regardless of the reason for discontinuation of the first TNF blocking agent. (First Release Sept 1 2009; J Rheumatol 2009;36:2171-7; doi:10.3899/jrheum.090054)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据